The prediction of EGFR mutation status and risk stratification in patients with NSCLC can be realized through multi-disciplinary and multi-dimensional, which addresses the limitations of biopsy tissue acquisition and saves the cost of gene detection. Here, EGFR is linked to non-small cell lung carcinoma.